Timing is everything: Clinical evidence supports pre-symptomatic treatment for spinal muscular atrophy

por Motyl, Anna A.L., Gillingwater, Thomas H.
Publicado 2022

Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy

por Motyl, Anna A L, Faller, Kiterie M E, Groen, Ewout J N, Kline, Rachel A, Eaton, Samantha L, Ledahawsky, Leire M, Chaytow, Helena, Lamont, Douglas J, Wishart, Thomas M, Huang, Yu-Ting, Gillingwater, Thomas H
Publicado 2020

The mitochondrial protein Sideroflexin 3 (SFXN3) influences neurodegeneration pathways in vivo

por Ledahawsky, Leire M., Terzenidou, Maria Eirini, Edwards, Ruairidh, Kline, Rachel A., Graham, Laura C., Eaton, Samantha L., van der Hoorn, Dinja, Chaytow, Helena, Huang, Yu‐Ting, Groen, Ewout J. N., Motyl, Anna A. L., Lamont, Douglas J., Tokatlidis, Kostas, Wishart, Thomas M., Gillingwater, Thomas H.
Publicado 2022

Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy

por Boyd, Penelope J., Tu, Wen-Yo, Shorrock, Hannah K., Groen, Ewout J. N., Carter, Roderick N., Powis, Rachael A., Thomson, Sophie R., Thomson, Derek, Graham, Laura C., Motyl, Anna A. L., Wishart, Thomas M., Highley, J. Robin, Morton, Nicholas M., Becker, Thomas, Becker, Catherina G., Heath, Paul R., Gillingwater, Thomas H.
Publicado 2017